Sana Biotechnology (NASDAQ:SANA) Shares Gap Up - What's Next?

Key Points

• Shares gapped up: Sana opened at $3.99 after a $3.21 close and last traded around $3.65 on heavy volume (~8.14M), representing roughly a 13.1% intraday rise.
• Analyst sentiment is mixed but tilted positive: six Buys, one Hold and one Sell produce a consensus "Moderate Buy" and an average price target of $8.20, while individual firms have moved ratings and targets in both directions.
• Sana is a clinical-stage company that missed quarterly estimates (EPS of ($0.16) vs. ($0.13) expected), trades with a negative P/E and a market cap of about $969M, and has roughly 88% institutional ownership, underscoring clinical-stage risk and cash-burn considerations.

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) shares gapped up prior to trading on Tuesday . The stock had previously closed at $3.21, but opened at $3.99. Sana Biotechnology shares last traded at $3.6460, with a volume of 8,137,808 shares.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SANA. Zacks Research cut shares of Sana Biotechnology from a "strong-buy" rating to a "hold" rating in a report on Tuesday, March 3rd. Wedbush upped their price objective on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock an "outperform" rating in a report on Tuesday. Weiss Ratings restated a "sell (e+)" rating on shares of Sana Biotechnology in a report on Monday, December 29th. Wall Street Zen cut shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a report on Saturday, February 7th. Finally, HC Wainwright cut their price objective on shares of Sana Biotechnology from $9.00 to $7.00 and set a "buy" rating on the stock in a report on Wednesday, March 4th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $8.20.

Sana Biotechnology Stock Up 13.1%

The stock's fifty day moving average price is $3.51 and its 200 day moving average price is $4.13. The stock has a market cap of $969.00 million, a PE ratio of -3.74 and a beta of 2.06.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.03). On average, equities research analysts expect that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sana Biotechnology

A number of institutional investors have recently made changes to their positions in SANA. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Sana Biotechnology during the third quarter valued at approximately $36,000. Lyell Wealth Management LP purchased a new stake in Sana Biotechnology in the third quarter worth approximately $37,000. TD Waterhouse Canada Inc. purchased a new stake in Sana Biotechnology in the third quarter worth approximately $37,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Sana Biotechnology in the third quarter worth approximately $39,000. Finally, Rockefeller Capital Management L.P. boosted its holdings in Sana Biotechnology by 74.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 9,588 shares of the company's stock worth $39,000 after purchasing an additional 4,088 shares during the last quarter. Hedge funds and other institutional investors own 88.23% of the company's stock.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.